EANS-News: CE mark granted for wound spray based on Sangui patent

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Patents, Copyright & Trademarks/Sales start

Subtitle: Sales start under Granulox brand name imminent

Witten (euro adhoc) - Based on a patent by Sangui, the technology for
a spray aiming at improved healing of chronic wounds is now
available. According to a notification by SastoMed GmbH a
certification as class III medical product was granted. Global
licensee SastoMed will be in charge of marketing and distribution.
The CE mark according to sections 6 and 7 of the Medical Devices Act
authorizes production, distribution and sales of the product in all
member countries of the European Union. SastoMed have also informed
SanguiBioTech GmbH that the market entry of the product is imminent.
SastoMed Managing Director Michael Sander said: "This is a definitive
breakthrough enabling us to capitalize on the great opportunities
this unique product offers. We now sell the only therapeutic which
can help to soothe the problem of hypoxia i.e. the lack of oxygen
supply to chronic wounds. This technology can be regarded as a
significant innovation in wound treatment. Already, we experience
numerous individual requests and a growing awareness among leading
wound management experts. We are excited to offer them a highly
effective supplement to the existing treatments." The CE mark
certification for Granulox was obtained only 16 months after the
founding of the joint venture company SastoMed by SanguiBioTech GmbH
and SanderStrothman GmbH and well ahead of the initial two year road
map. Numerous additional inquiries were required to prepare the
demanding documentation for the certification as class III medical
product, cornerstone of the process of converting the patent into a
production process, impeccable both from an economic and
authorization point of view. In addition, preparatory works included
the developing of completely new manufacturing processes yielding
considerable efficiency improvements. "With the imminent market entry
of the product our company enters a new stage", Hubertus Schmelz,
Managing Director of SanguiBioTech GmbH emphasized. "It also confirms
that the cooperation with SanderStrothmann was and continues to be a
decisive step ahead for us with both sides now benefiting from the
professionalism and the good mutual relationship established over the
past years." Details of the sales plan as well as of future
activities are to be disclosed in due course.

Further inquiry note:
Dr. Joachim Fleing
Fon: +49 (160) 741 27 17
Fax: +49 (2302) 915 191
e-mail: fleing@sangui.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Sangui Bio Tech International Inc.
Alfred-Herrhausen-Strasse 44
D-58455 Witten
phone: +49(0)2302 915-200
FAX: +49(0)2302 915-191
mail: info@sangui.de
WWW: http://www.sanguibiotech.com
sector: Biotechnology
ISIN: DE0000906757
indexes:
stockmarkets: free trade: Hamburg, New York
language: English